Allergan, Inamed forge ahead
This article was originally published in The Gray Sheet
Executive Summary
Allergan and Inamed sign a definitive merger agreement Dec. 20 after Inamed's board unanimously approved Allergan's $3.2 bil. bid Dec. 15. Forty-five percent of aggregate Inamed shares tendered will be exchanged for cash and 55% will be exchanged for shares of Allergan common stock. As expected, Inamed divested its Reloxin botulinum toxin product by entering into a termination agreement with Ipsen Ltd., restoring Ipsen's rights to the product (1"The Gray Sheet" Dec. 19, 2005, p. 4). Inamed and Allergan say they are working with the Federal Trade Commission and other regulatory agencies, but do not provide a definitive timeline for merger completion...
You may also be interested in...
Inamed’s Board Embraces Allergan’s Offer After Dissolving Deal With Medicis
Inamed's board unanimously approved a proposed plan to merge with Allergan for $3.2 bil. on Dec. 15, two days after rejecting Medicis' $2.8 bil. acquisition offer
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.